Mutant RAS Inhibitor Compounds for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancer, particularly those targeting aberrant RAS proteins, have limited effectiveness due to challenges in specifically inhibiting oncogenic RAS function within cells, as most RAS proteins are intracellular and difficult to target with conventional methods, and there is a need for molecules that can penetrate cells to bind and inhibit RAS-effector protein interactions with high affinity and specificity.
Innovation Solution
Development of compounds that can penetrate cells and specifically inhibit RAS-effector protein interactions, particularly those involving aberrant RAS proteins, by binding to RAS and disrupting its interactions with effector proteins such as RAF and PI3K, utilizing novel chemical structures defined by Formula Ih, li, Ij, and Ik, and their salts or solvates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapy methods are used to target RAS proteins, then treatment coverage is provided, but effectiveness is limited due to inability to specifically inhibit oncogenic RAS function within cells
Solution Approach 1:
The patent employs small molecule compounds as intermediaries that can penetrate cell membranes and specifically bind to RAS proteins. These compounds act as mediators between the extracellular environment and intracellular RAS targets, enabling specific inhibition of RAS-effector interactions while overcoming the barrier of cellular accessibility.
Solution Approach 2:
The invention utilizes compounds with specific molecular parameters (size, lipophilicity, binding affinity) that enable them to penetrate cells and bind to RAS proteins with high specificity. By optimizing these physical-chemical parameters, the compounds achieve both cellular penetration and specific target binding, resolving the contradiction between accessibility and effectiveness.
2Reliability
If RAS-effector protein interactions are inhibited with high affinity, then oncogenic RAS activity is neutralized, but specificity must be maintained to avoid affecting wild-type RAS function
Solution Approach 1:
The patent designs compounds that target specific local features of mutant RAS proteins, such as unique conformational changes or exposed surfaces created by mutations. This local quality approach allows high-affinity binding to mutant RAS while maintaining selectivity against wild-type RAS, as the compounds exploit mutation-specific structural characteristics.
Solution Approach 2:
Instead of trying to enhance binding to wild-type RAS and then discriminate against mutants, the invention inverts the approach by designing compounds that specifically recognize and bind to mutation-induced structural changes. This inversion strategy naturally provides both high affinity for mutant RAS and specificity against wild-type forms.
Data Source
Figure 1
AI summary
The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.